Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) shares dropped 1.9% during trading on Friday . The company traded as low as $0.60 and last traded at $0.60. Approximately 48,096 shares traded hands during trading, a decline of 42% from the average daily volume of 83,511 shares. The stock had previously closed at $0.61.

Analysts Set New Price Targets

TLPH has been the topic of a number of research analyst reports. RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a research report on Tuesday, January 28th. Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Talphera in a research report on Tuesday, January 21st. Finally, Rodman & Renshaw began coverage on shares of Talphera in a research report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price objective on the stock.

Talphera Trading Down 1.9 %

The company has a market cap of $10.23 million, a P/E ratio of -0.87 and a beta of 0.29. The stock’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.78.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Rosalind Advisors Inc. bought a new position in Talphera, Inc. (NASDAQ:TLPH) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera comprises 0.4% of Rosalind Advisors Inc.’s portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera at the end of the most recent quarter. 37.67% of the stock is currently owned by hedge funds and other institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.